Reduced expression of microRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.

Conclusion Our findings indicate that microRNA-27a negatively regulates SLC7A11 in cisplatin-resistant bladder cancer, and shows promise as a marker for patients likely to benefit from cisplatin-based chemotherapy. SLC7A11 inhibition with sulfasalazine may be a promising therapeutic approach to the treatment of cisplatin-resistant disease.
PMID: 24516043 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - February 10, 2014 Category: Cancer & Oncology Authors: Drayton RM, Dudziec E, Peter S, Bertz S, Hartmann A, Bryant HE, Catto JW Tags: Clin Cancer Res Source Type: research